ZEFIT is a biotech company that uses zebrafish models for early-stage drug research, focusing on anticancer drug development. It uses gene editing, automation, and AI to speed up the testing process, collaborating with over 50 biotech partners and expanding its global pharmaceutical research presence.

Advantages of Using Zebrafish in Drug Development:

Zebrafish, with shared genes with humans, aid researchers in comprehending human body functions and disease development, facilitating the creation of personalized treatments for specific illnesses.

Zebrafish models aid in early detection of molecular targets and pathways, making them ideal for proof-of-concept and early validation of new drug candidates.

Zebrafish research yields promising results in early-stage studies, benefiting major pharmaceutical companies like Novartis and Pfizer, which are reducing research and development costs and supporting regulatory applications like IND submissions.

Zebrafish research has been recognized as robust enough to support regulatory submissions, thereby validating its reliability in preclinical studies.

Zebrafish, once used in drug research, faced challenges in accurately delivering drugs, leading to inconsistent results. However, recent advancements in drug delivery methods, such as oral dosing and intravenous injections, allow for more precise and advanced drug studies.

Transparent embryos enable real-time, in vivo observation of biological processes, enabling real-time monitoring of drug effects on development, behavior, and organ function.

Zebrafish enables researchers to rapidly test numerous drug compounds simultaneously, saving time and resources during the early stages of drug.

Zebrafish are cost-effective, flexible, and easy to work with, making them ideal for university labs and large pharmaceutical companies.

If you are looking for an anticancer drug discovery, you can find them at ZEFIT.

Click here if you are interested in ZEFIT services.

View more: Zebrafish Solutions for Preclinical Drug Development.